Healthcare 844

Stocks in the Healthcare sector are up 17.2% so far in 2021.

Rhythm Pharmaceuticals, Inc. (RYTM) | Daily Alert July 30
Rhythm Pharmaceuticals announced an exclusive distribution agreement with Medison Pharma to commercialize Imcivree in Israel. With the exclusive distribution agreement with Medison Pharma, positive Committee for Medicinal Products for Human Use (CHMP) opinion for Imcivree, and dataflow paving the way for potential setmelanotide utility in additional MC4R-driven obesity indications, we reiterate our BUY.

Medison is a global pharmaceutical company and one of the top three in Israel by sales. Medison Pharma provides a full spectrum of services, including registration, reimbursement, distribution, marketing for biotech companies looking to enter markets in Israel. We view the expansion of RYTM’s commercial footprint into Israel as a positive.
Arlinda Lee, Ph.D., and Benedict Shim, Canaccord Genuity Research, canaccordgenuity.com, July 23, 2021

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Enter Your Log In Credentials

This setting should only be used on your home or work computer.

Need Assistance?

Call Financial Freedom Federation Customer Service at
(800) 777-2658

Send this to a friend